Investment
Features
FeesSafety
Academy
More
Pluang+

Compare A O Smith Corp (AOS) vs Heron Therapeutics Inc (HRTX) Price & Performance

A O Smith CorpTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

A O Smith Corp vs Heron Therapeutics Inc — how do they compare? A O Smith Corp trades at $63.65 (market cap $8.65B), while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: A O Smith Corp is far larger — about 140.7× Heron Therapeutics Inc's market cap, and A O Smith Corp pays a 2.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

AOSHRTX
Market Cap
$8.65B$61.47M
Sector
IndustrialsHealth
52-Week High
$80.47$1.49
52-Week Low
$55.78$0.32
Enterprise Value
$9.15B$168.21M
Dividend Yield
2.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

A O Smith Corp

A. O. Smith Corporation (AOS) trades at $62.47, showing modest daily gains. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential near-term overbought conditions. Fundamentally, the company maintains solid profitability with a net income margin of 13.15% and ROE of 27.13%, supported by consistent revenue around $3.8 billion. Recent Q2 2026 earnings beat expectations, but Q1 2026 was a miss, reflecting some volatility. A quarterly dividend of $0.36 provides income appeal.

The outlook for AOS is cautiously optimistic, with a consensus price target of $67.25 implying upside potential. Strengths include robust cash flow from operations and high return metrics. Key risks involve exposure to input cost pressures, competitive markets, and mixed quarterly earnings performance. Investor sentiment is balanced, with analyst ratings leaning Hold. The stock presents a value opportunity for those comfortable with industrial sector cyclicality.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About A O Smith Corp

A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.

Read more on AOS

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX